Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

We recently published a list of These 10 Stocks Lost This Much Today. In this article, we are going to take a look at where ...

This symposium, ‘A case-based approach to navigating treatment switch in late-onset Pompe Disease (LOPD)’, was held at the ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

In a May 15, 2025, opinion, Judge Dabney Friedrich of the US District Court for the District of Columbia denied drugmakers’ motions for ...

Nvidia falls after rallying Thursday, Marvell’s latest earnings fail to impress Wall Street, and Gap and American Eagle ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.